Liver biopsy was historically the definitive iron-burden assessment - invasive and difficult to repeat. MRI-based LIC measurement (R2 or T2*) has transformed practice by providing accurate, non-invasive, repeatable iron quantification.
Why the Liver? #
The liver is the dominant iron storage organ - containing 60-80% of body iron stores in overloaded patients. LIC is therefore the single most informative measure of total-body iron burden.
Two Main MRI Methods #
- R2 (FerriScan) - validated, FDA-cleared; 1.5T scanner; sends images to central analysis service; robust across iron ranges
- T2* - widely available on modern scanners; faster, local analysis possible; validated at 1.5T
LIC Interpretation (mg Fe/g dry weight) #
| LIC Range | Typical Implication |
|---|---|
| < 2 (normal) | Normal / reference |
| 2-5 | Mild iron loading |
| 5-15 | Moderate - intensify chelation |
| > 15 | Severe - aggressive chelation; cardiac T2* assessment |
Why LIC Beats Ferritin #
- Not confounded by inflammation
- Accurate in SCD and MDS where ferritin is unreliable
- Directly quantifies the organ iron store
- Tracks treatment response reliably
Clinical Integration #
Combine LIC with ferritin trend, cardiac T2*, renal / hepatic function and clinical assessment. LIC every 6-12 months supports dose decisions - particularly at inflection points (starting therapy, dose titration, treatment response evaluation).
Access Considerations #
MRI access is uneven globally - some centres have 1.5T scanners with validated R2* / T2* protocols; others rely on ferritin alone. Expanding MRI availability in thalassemia and SCD high-prevalence regions is a public-health priority that directly improves chelation dosing.
See Pharmacodynamics and Monitoring Guidelines.